» Articles » PMID: 23422144

Immunization of Pigs with a Type 2 Modified Live PRRSV Vaccine Prevents the Development of a Deadly Long Lasting Hyperpyrexia in a Challenge Study with Highly Pathogenic PRRSV JX143

Overview
Journal Vaccine
Date 2013 Feb 21
PMID 23422144
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Porcine reproductive and respiratory syndrome virus (PRRSV) has been confirmed to be the underlying cause of the so-called 'porcine high fever disease' (PHFD), a disease that emerged in China in 2006 and subsequently spread over South East Asia. The aim of this study was to investigate whether animals challenged with the Chinese highly pathogenic PRRSV JX143 would be protected by vaccination with single dose of a type 2 modified live virus (MLV) vaccine. Forty-four pigs 17-19 days of age were weighed and randomly assigned to either vaccination with subsequent challenge (V/C, n=20), challenge only (NV/C, n=12) and no vaccination and no challenge (strict controls, n=12). Pigs of the challenged groups (V/C and NV/C) were inoculated intranasally 27 days post-vaccination with PRRSV JX143. Animals were monitored during the subsequent 21 days post challenge and were necropsied at the end of the experiment on day 49. Observations and measurements included body temperature, clinical scores for behavior/general condition, cough and breathing pattern, mortality, serological response and PRRSV viremia via RNA detection. Challenge in the NV/C pigs resulted in 100% morbidity and 67% mortality whereas all vaccinated pigs survived. There was a close association between hyperpyrexia (fever over 41°C) and incidence in mortality, which was completely prevented by vaccination. Clinical symptoms were less severe, and of transient nature only, in the vaccinated pigs. Vaccination did not prevent infection, but reduced the impact of clinical disease and prevented hyperpyrexia associated mortality.

Citing Articles

Role of genetic factors in different swine breeds exhibiting varying levels of resistance/susceptibility to PRRSV.

You X, Li G, Lei Y, Xu Z, Zhang P, Yang Y Virus Res. 2023; 326:199057.

PMID: 36731630 PMC: 10194364. DOI: 10.1016/j.virusres.2023.199057.


Change of Gut Microbiota in PRRSV-Resistant Pigs and PRRSV-Susceptible Pigs from Tongcheng Pigs and Large White Pigs Crossed Population upon PRRSV Infection.

Wang T, Guan K, Su Q, Wang X, Yan Z, Kuang K Animals (Basel). 2022; 12(12).

PMID: 35739841 PMC: 9219425. DOI: 10.3390/ani12121504.


The Antiviral Effect of Root Polysaccharide against NADC30-like PRRSV by Transcriptome and Proteome Analysis.

Jiang D, Zhang L, Zhu G, Zhang P, Wu X, Yao X Int J Mol Sci. 2022; 23(7).

PMID: 35409050 PMC: 8998840. DOI: 10.3390/ijms23073688.


Evaluation of Four Commercial Vaccines for the Protection of Piglets against the Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus (hp-PRRSV) QH-08 Strain.

Ding Y, Wubshet A, Ding X, Zhang Z, Li Q, Dai J Vaccines (Basel). 2021; 9(9).

PMID: 34579257 PMC: 8471949. DOI: 10.3390/vaccines9091020.


Commercial PRRS Modified-Live Virus Vaccines.

Chae C Vaccines (Basel). 2021; 9(2).

PMID: 33671826 PMC: 7926738. DOI: 10.3390/vaccines9020185.